Nolan Priedigkeit, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Estrogen Receptor alpha | 6 | 2022 | 577 | 0.730 |
Why?
|
Breast Neoplasms | 16 | 2022 | 20774 | 0.630 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2021 | 8425 | 0.490 |
Why?
|
Estrogens | 1 | 2021 | 1562 | 0.460 |
Why?
|
Hirschsprung Disease | 1 | 2015 | 155 | 0.450 |
Why?
|
Receptor, erbB-2 | 2 | 2022 | 2410 | 0.400 |
Why?
|
Sequence Analysis, RNA | 2 | 2017 | 2011 | 0.360 |
Why?
|
Bone Neoplasms | 2 | 2022 | 2522 | 0.340 |
Why?
|
Evolution, Molecular | 2 | 2015 | 1937 | 0.330 |
Why?
|
Calcinosis | 1 | 2017 | 1497 | 0.320 |
Why?
|
Mutation | 8 | 2022 | 29717 | 0.300 |
Why?
|
Gene Regulatory Networks | 1 | 2015 | 1707 | 0.280 |
Why?
|
Brain Neoplasms | 3 | 2020 | 8829 | 0.220 |
Why?
|
Nuclear Receptor Coactivator 3 | 1 | 2021 | 53 | 0.200 |
Why?
|
Inflammatory Breast Neoplasms | 1 | 2022 | 137 | 0.190 |
Why?
|
DNA Copy Number Variations | 3 | 2021 | 1940 | 0.190 |
Why?
|
Gene Expression Profiling | 6 | 2021 | 9410 | 0.180 |
Why?
|
Cadherins | 2 | 2021 | 906 | 0.170 |
Why?
|
ADAM Proteins | 1 | 2020 | 242 | 0.170 |
Why?
|
Cyclin-Dependent Kinase Inhibitor Proteins | 1 | 2018 | 55 | 0.170 |
Why?
|
Biomimetic Materials | 1 | 2020 | 179 | 0.170 |
Why?
|
Receptors, Angiotensin | 1 | 2017 | 142 | 0.150 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 2017 | 152 | 0.150 |
Why?
|
Genes, erbB-2 | 1 | 2017 | 162 | 0.150 |
Why?
|
Neoplastic Cells, Circulating | 2 | 2022 | 933 | 0.150 |
Why?
|
Allyl Compounds | 1 | 2016 | 23 | 0.140 |
Why?
|
CARD Signaling Adaptor Proteins | 1 | 2017 | 156 | 0.140 |
Why?
|
Melanoma | 1 | 2015 | 5462 | 0.140 |
Why?
|
Retinal Dehydrogenase | 1 | 2016 | 74 | 0.140 |
Why?
|
Mutant Chimeric Proteins | 1 | 2015 | 22 | 0.140 |
Why?
|
Carcinoma, Lobular | 1 | 2020 | 484 | 0.140 |
Why?
|
Gene Amplification | 2 | 2018 | 1062 | 0.140 |
Why?
|
Cyclin-Dependent Kinase 6 | 1 | 2018 | 322 | 0.140 |
Why?
|
Histone Deacetylases | 1 | 2021 | 729 | 0.140 |
Why?
|
Karyopherins | 1 | 2016 | 132 | 0.130 |
Why?
|
Computational Biology | 2 | 2021 | 3518 | 0.130 |
Why?
|
Sulfides | 1 | 2016 | 166 | 0.130 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2018 | 535 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2022 | 1052 | 0.120 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2018 | 5163 | 0.120 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2020 | 1101 | 0.110 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 2022 | 1884 | 0.110 |
Why?
|
DNA, Neoplasm | 2 | 2018 | 1758 | 0.110 |
Why?
|
Gene Fusion | 1 | 2015 | 371 | 0.110 |
Why?
|
Aromatase | 1 | 2012 | 146 | 0.110 |
Why?
|
Chromosomes | 1 | 2015 | 595 | 0.100 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2016 | 867 | 0.100 |
Why?
|
Isoenzymes | 1 | 2016 | 1725 | 0.100 |
Why?
|
Recurrence | 2 | 2021 | 8333 | 0.100 |
Why?
|
Genome, Human | 2 | 2015 | 4420 | 0.090 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2020 | 2906 | 0.090 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2183 | 0.090 |
Why?
|
Protein Structure, Tertiary | 2 | 2015 | 3847 | 0.090 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2018 | 1509 | 0.090 |
Why?
|
Repressor Proteins | 1 | 2021 | 3020 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2019 | 3557 | 0.090 |
Why?
|
Cell Proliferation | 4 | 2021 | 10472 | 0.090 |
Why?
|
Recombinant Fusion Proteins | 1 | 2018 | 3770 | 0.090 |
Why?
|
NF-kappa B | 1 | 2017 | 2500 | 0.080 |
Why?
|
Aromatase Inhibitors | 1 | 2012 | 491 | 0.080 |
Why?
|
Female | 20 | 2022 | 379592 | 0.080 |
Why?
|
Forkhead Transcription Factors | 1 | 2016 | 1613 | 0.080 |
Why?
|
Mutagenesis | 1 | 2012 | 1263 | 0.080 |
Why?
|
Peptides | 1 | 2020 | 4392 | 0.080 |
Why?
|
Ovarian Neoplasms | 2 | 2016 | 4823 | 0.080 |
Why?
|
Neoplastic Stem Cells | 1 | 2016 | 1376 | 0.080 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2015 | 1581 | 0.080 |
Why?
|
Nerve Tissue Proteins | 1 | 2020 | 4465 | 0.080 |
Why?
|
Kruppel-Like Transcription Factors | 1 | 2010 | 504 | 0.080 |
Why?
|
Gene Silencing | 1 | 2013 | 1538 | 0.070 |
Why?
|
Translocation, Genetic | 1 | 2012 | 1417 | 0.070 |
Why?
|
Oncogenes | 1 | 2012 | 1263 | 0.070 |
Why?
|
Humans | 23 | 2022 | 742088 | 0.060 |
Why?
|
Neoplasm Metastasis | 3 | 2021 | 4839 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2020 | 9185 | 0.060 |
Why?
|
RNA, Messenger | 2 | 2018 | 13029 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3691 | 0.060 |
Why?
|
Obesity, Morbid | 1 | 2013 | 1204 | 0.050 |
Why?
|
Prognosis | 5 | 2022 | 29010 | 0.050 |
Why?
|
RecQ Helicases | 1 | 2022 | 54 | 0.050 |
Why?
|
Cisplatin | 2 | 2022 | 1637 | 0.050 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2012 | 2940 | 0.050 |
Why?
|
Active Transport, Cell Nucleus | 2 | 2016 | 438 | 0.050 |
Why?
|
Cell Cycle Proteins | 1 | 2013 | 3444 | 0.050 |
Why?
|
Cell Nucleus | 1 | 2010 | 2968 | 0.050 |
Why?
|
Software | 1 | 2015 | 4434 | 0.050 |
Why?
|
Tumor Cells, Cultured | 2 | 2020 | 6313 | 0.050 |
Why?
|
Mice, Nude | 2 | 2017 | 3689 | 0.050 |
Why?
|
Antigens, CD | 2 | 2021 | 4024 | 0.040 |
Why?
|
Genomic Instability | 1 | 2022 | 695 | 0.040 |
Why?
|
Proto-Oncogene Proteins | 1 | 2010 | 4553 | 0.040 |
Why?
|
Lysine | 1 | 2022 | 1008 | 0.040 |
Why?
|
Recombination, Genetic | 1 | 2022 | 1586 | 0.040 |
Why?
|
Acrylates | 1 | 2016 | 89 | 0.040 |
Why?
|
Organoids | 1 | 2022 | 692 | 0.030 |
Why?
|
Tamoxifen | 1 | 2021 | 980 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2022 | 1333 | 0.030 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2021 | 713 | 0.030 |
Why?
|
Chick Embryo | 1 | 2017 | 981 | 0.030 |
Why?
|
Immunoconjugates | 1 | 2022 | 897 | 0.030 |
Why?
|
Algorithms | 1 | 2015 | 13853 | 0.030 |
Why?
|
Platinum | 1 | 2016 | 232 | 0.030 |
Why?
|
Hydrazines | 1 | 2016 | 220 | 0.030 |
Why?
|
Cohort Studies | 1 | 2017 | 40450 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2022 | 2186 | 0.030 |
Why?
|
Survival Rate | 2 | 2019 | 12773 | 0.030 |
Why?
|
Gene Order | 1 | 2013 | 176 | 0.030 |
Why?
|
Physical Chromosome Mapping | 1 | 2013 | 183 | 0.030 |
Why?
|
Mice | 5 | 2019 | 81045 | 0.030 |
Why?
|
Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2014 | 187 | 0.030 |
Why?
|
Eye Proteins | 1 | 2016 | 644 | 0.030 |
Why?
|
Consanguinity | 1 | 2013 | 456 | 0.030 |
Why?
|
CA-125 Antigen | 1 | 2014 | 279 | 0.020 |
Why?
|
Saccharomyces cerevisiae | 1 | 2022 | 2749 | 0.020 |
Why?
|
Animals | 6 | 2020 | 168561 | 0.020 |
Why?
|
Nuclear Export Signals | 1 | 2010 | 9 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2014 | 731 | 0.020 |
Why?
|
Triazoles | 1 | 2016 | 907 | 0.020 |
Why?
|
Apoptosis | 2 | 2017 | 9715 | 0.020 |
Why?
|
Nuclear Localization Signals | 1 | 2010 | 80 | 0.020 |
Why?
|
Antineoplastic Agents | 1 | 2014 | 13655 | 0.020 |
Why?
|
Glucose Tolerance Test | 1 | 2013 | 1150 | 0.020 |
Why?
|
Alternative Splicing | 1 | 2015 | 1118 | 0.020 |
Why?
|
Disease-Free Survival | 1 | 2021 | 6891 | 0.020 |
Why?
|
Conserved Sequence | 1 | 2013 | 1202 | 0.020 |
Why?
|
Gene Targeting | 1 | 2013 | 880 | 0.020 |
Why?
|
Phenotype | 2 | 2021 | 16331 | 0.020 |
Why?
|
Amino Acid Sequence | 2 | 2013 | 13814 | 0.020 |
Why?
|
Half-Life | 1 | 2010 | 658 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2723 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2013 | 18112 | 0.020 |
Why?
|
Adult | 3 | 2019 | 213712 | 0.020 |
Why?
|
Protein Stability | 1 | 2010 | 556 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2016 | 16665 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2017 | 3504 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7289 | 0.020 |
Why?
|
Genetic Linkage | 1 | 2013 | 2422 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2016 | 3612 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 2013 | 4322 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2017 | 2633 | 0.020 |
Why?
|
Middle Aged | 2 | 2019 | 213127 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2019 | 39004 | 0.020 |
Why?
|
Cell Survival | 1 | 2016 | 5872 | 0.020 |
Why?
|
Pedigree | 1 | 2013 | 4646 | 0.020 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2018 | 3585 | 0.020 |
Why?
|
Cell Movement | 1 | 2017 | 5212 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2699 | 0.010 |
Why?
|
Signal Transduction | 2 | 2018 | 23387 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2019 | 13921 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2019 | 21719 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2013 | 3861 | 0.010 |
Why?
|
Genotype | 1 | 2013 | 12946 | 0.010 |
Why?
|
Insulin | 1 | 2013 | 6575 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2013 | 14554 | 0.010 |
Why?
|
Transcription Factors | 1 | 2016 | 12164 | 0.010 |
Why?
|
Cell Line | 1 | 2010 | 15994 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2013 | 18006 | 0.010 |
Why?
|
Young Adult | 1 | 2013 | 56350 | 0.000 |
Why?
|
Neoplasms | 1 | 2015 | 21596 | 0.000 |
Why?
|
Male | 1 | 2013 | 349538 | 0.000 |
Why?
|